TherapeuticsMD (NASDAQ:TXMD) Posts Earnings Results, Beats Expectations By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) announced its quarterly earnings results on Tuesday. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $6.13, FiscalAI reports. The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative net margin of 6.64% and a negative return on equity of 1.09%.

TherapeuticsMD Stock Performance

Shares of TXMD stock remained flat at $2.08 during trading hours on Thursday. 1,133 shares of the stock were exchanged, compared to its average volume of 49,714. TherapeuticsMD has a 12 month low of $0.99 and a 12 month high of $2.95. The business has a fifty day moving average price of $2.05 and a two-hundred day moving average price of $2.13. The firm has a market cap of $24.07 million, a P/E ratio of 34.67 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TherapeuticsMD in a report on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, TherapeuticsMD has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC raised its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the period. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.